ARTICLE
thresholdwasthenmanuallyadjustedtoensurethatonlyspeci cTHstainingwasidenti ed.Theventriclehastwolayersofmusclesetatdifferentangles;therefore,eachsectionincludedsomenerve brescutlongitudinallyalongtheplaneofthesectionandother brescutincross-sectionandappearingassmallrounddots.Thus,speci ccriteriaforsizeandshapewerenotusedinouranalysis.Innervationdensitywasexpressedasthepercentofareathatwasabovethethreshold(THþ bres).Eachimagewasquanti edbytwoindependentobservers.
Infarctsize.Infarctswereidenti edwith brinogenstainingandinfarctsizewasquanti edusingeight10-mmsections,B200mmapartobtainedfrommatchedlevelsfromeachheart.Imagesweretakenoftheentiresection,andtheLVandinfarctareasweremeasuredbyoutliningtherespectiveregionsusingthefreehandselectiontoolinImageJ.InfarctsizewasthencalculatedasapercentageoftheLVarea[(infarctarea/LVarea)Â100].Sectionswereobtainedfromtheupper,middleandlowerregionsoftheinfarctineachheart.
NEcontent.NElevelsinhearttissueweremeasuredusingHPLCwithelectro-chemicaldetection.Frozen,pulverizedtissuewasweighed,andthenhomogenizedin0.2Mperchloricacidand0.5mMdihydroxybenzylamine(DHBA).Thetissuewasrefrigeratedfor1handcentrifugedat14,000r.p.m.for4min.Supernatantwasadsorbedonalumina,followedby15minoftumbling.Thealuminawaswashedtwicewith1.0mlofH2Owithcentrifugationsinbetween.TheNEwasdesorbedfromthealuminawith150mlof0.1Mperchloricacid.Fifty-microlitrealiquotswerefractionatedbyreversed-phaseHPLC(C18;5mmparticlesize,Rainin)usingamobilephasecontaining75mMsodiumphosphate(pH3.0),360mglÀ1ofsodiumoctanesulfonate,100mllÀ1triethylamineand3.0%acetonitrile.Acou-lometricdetector(Coulchem,ESA)wasusedtodetectandquantifyNEand
DHBA.NEstandards(0.5mM)wereprocessedinparallelwithtissuesamplesandinterspersedthroughouttheHPLCrun.RetentiontimeforNEwas5.0minandforDHBAwas8.5min.
LangendorffperfusionanddualopticalmappingofVmandCa2þ.Micewereanaesthetizedwithpentobarbitalsodium(150mgkgÀ1,IP)containing120IUofheparin.Followingamidsternalincision,heartswererapidlyexcisedandLan-gendorff-perfusedat37°Cwithoxygenated(95%O2and5%CO2)modi edTyrode’ssolutionofthefollowingcomposition(inmmollÀ1):NaCl128.2,CaCl21.3,KCl4.7,MgCl21.05,NaH2PO41.19,NaHCO320andglucose11.1(pH7.4).Flowrate(1.5–3.5mlminÀ1)wasadjustedtomaintainaperfusionpressureof60–80mmHg.Onelea etofthemitralvalvewascarefullydamagedwithsharpforcepsinsertedthroughthepulmonaryveintopreventsolutioncongestionintheLVcavityaftersuppressionofventricularcontraction.TwoAg/AgCldiscelectrodeswerepositionedinthebathtorecordanECGanalogoustoaleadIcon guration.ECGwascontinuouslyrecordedthroughoutthedurationoftheexperiment.AbipolarelectrodewaspositionedonthebaseoftheLVepicardiumforpacing,whichwasperformedatabasiccyclelengthof150msusinga2-mspulsewidthattwicethediastolicthreshold.
Heartswereloadedwiththe uorescentintracellularCa2þindicatorRhod-2AM(MolecularProbes,Eugene,OR;50mlof1mgmlÀ1inDMSOcontaining10%pluronicacid)andweresubsequentlystainedwiththevoltage-sensitivedyeRH237(MolecularProbes;10mlof1mgmlÀ1inDMSO).Blebbistatin(TocrisBioscience,Ellisville,MO;10–20mM)wasaddedtotheperfusatetoeliminatemotionartifactduringopticalrecordings.TheanteriorepicardialsurfacewasexcitedusingLEDlightsourcescentredat530nmandbandpass- lteredfrom511to551nm(LEX-2,SciMedia,CostaMesa,CA)andfocuseddirectlyonthesurfaceofthepreparation.Theemitted uorescencewascollectedthrougha50-mmobjective(Nikon,Japan)andsplitwithadichroicmirrorat630nm(Omega,Brattleboro,VT).Thelongerwavelengthmoiety,containingtheVmsignal,waslongpass- lteredat700nmandtheshorterwavelengthmoiety,containingtheCa2þsignal,wasbandpass- lteredbetween574and606nm.Theemitted uorescencesignalswererecordedusingtwoCMOScameras(MiCamUltima-L,SciMedia)withasamplingrateof1kHzand100Â100pixelswitha10Â10mm eldofview38.
Mappingexperimentalprotocol.Followingdyeloading,baselineelectro-physiologicalparameterswererecordedduringnormalsinusrhythmaswellasLVepicardialpacingatintervalsof150and100ms.Heartsweresubjectedtotyramineinfusion(20mM)followedbyawashoutperiod.Heartswerethensubjectedtoacuteb-ARstimulationwithISO(1mM).Opticalrecordingsweretakenevery5minfollowingtreatment,andECGwascontinuouslyrecorded.Following15minofISOtreatment,theb-ARblockerpropranolol(10mM)wasaddedtotheper-fusate.Opticalrecordingswererepeatedevery5minfor15min.
Opticalmappingdataanalysis.Opticalmappingdataanalysiswasperformedusingtwocommerciallyavailableanalysisprogrammes(BV_Analyze,Brainvision,Tokyo,JapanandOptiq,Cairn,UK).VmandCa2þdatasetswerespatiallyalignedandprocessedwithaGaussianspatial lter(radius3pixels).ForbothactionpotentialsandCaT,activationtimewasdeterminedasthetimeat50%ofthemaximalamplitude.Foractionpotentials,repolarizationtimeat30and90%returntobaselinewereusedtocalculateAPD(APD30andAPD90).RelativeAPD30and
8
NATURECOMMUNICATIONS|DOI:10.1038/ncomms7235
APD90usedinrestitutioncurveswerecalculatedasaratioofS2APD/S1APD.Conductionvelocitywascalculatedalongavectorfromthebasetoapexusingapolynomial ttingalgorithmpreviouslydescribedinref.54.Separate
measurementsoflongitudinalandtransverseconductionvelocitywerenot
determinedbecauseofthebasalpacinglocationanddisruptionof breorientationintheinfarctregion.DiastolicCa2þelevationwasmeasuredasthepercentageofdiastolicCa2þincreaserelativetothefollowingCaTamplitudeatbaselineand15minposttreatment.TheaveragediastolicCa2þelevationwascalculatedforeachheartbyaveragingallCa2þsignalsfromtheentireanteriorsurfaceoftheheartwithintheopticalmapping eldofview.PVCincidencewasdeterminedfromthecontinuousECGrecordingasthenumberofPVCsthatoccurredduringa20-minperiodofbaselineactivity(beforeinitiationoftreatment)andduringthe20minoftreatment.Arrhythmiaseveritywasscoredonthebasisofthemostseverearrhythmiaobservedineachheartovera20-mincontinuousECGrecording(0¼noPVCs,1¼singlePVCs,2¼bigeminyorsalvosand3¼ventriculartachycardia)39.
Thespectralmethod,whichhasbeenusedclinicallyfordetectingmicro-voltT-wavealternans55,wasusedtodetectthepresenceofCaTalternansandAPDalternans56.Thespectralmethodwaschosenbecauseofitshighsensitivityandrelativeimmunitytonoise.Thisapproachallowedustodeterminewhetheranareawithinthemapping eldofviewwasexperiencingsigni cantAPDorCaT
alternans(greaterthanthebackgroundnoiselevels)aswellasthespatialextentofsigni cantalternans.AspectralmagnitudeofZ2wasusedastheminimumthresholdforsigni cantAPDorCaTalternans,correspondingtoabeat-to-beatchangeinAPD90Z5msorbeat-to-beatchangeinCaTamplitudeZ5%,respectively57.
Statistics.Student’st-testswereusedtocomparetwogroups.Datasetsthatincludedmorethantwogroupswereanalysedbyone-wayanalysisofvariance(ANOVA)usingtheTukeyposthoctesttocompareallconditions.Forexperimentscomparingdifferentsurgicalgroupsandgenotypesatwo-wayANOVAwascarriedoutusingtheBonferroniposthoctest.AllstatisticalanalyseswerecarriedoutusingPrism5.0.
References
1.Solomon,S.D.etal.Suddendeathinpatientswithmyocardialinfarction
andleftventriculardysfunction,heartfailure,orboth.N.Engl.J.Med.352,2581–2588(2005).
2.Jalife,J.Ventricular brillation:mechanismsofinitiationandmaintenance.
Annu.Rev.Physiol.62,25–50(2000).
3.Nademanee,K.,Taylor,R.,Bailey,W.E.,Rieders,D.E.&Kosar,E.M.
Treatingelectricalstorm:sympatheticblockadeversusadvancedcardiaclifesupport-guidedtherapy.Circulation102,742–747(2000).
4.Basu,S.etal.Bene cialeffectsofintravenousandoralcarvediloltreatmentin
acutemyocardialinfarction.Aplacebo-controlled,randomizedtrial.Circulation96,183–191(1997).
5.Billman,G.E.,Castillo,L.C.,Hensley,J.,Hohl,C.M.&Altschuld,R.A.
Beta2-adrenergicreceptorantagonistsprotectagainstventricular brillation:invivoandinvitroevidenceforenhancedsensitivitytobeta2-adrenergicstimulationinanimalssusceptibletosuddendeath.Circulation96,1914–1922(1997).
6.Exner,D.V.etal.Beta-blockeruseandsurvivalinpatientswithventricular
brillationorsymptomaticventriculartachycardia:theAntiarrhythmicsVersusImplantableDe brillators(AVID)trial.J.Am.Coll.Cardiol.34,325–333(1999).
7.Schwartz,P.J.etal.Preventionofsuddencardiacdeathaftera rstmyocardial
infarctionbypharmacologicorsurgicalantiadrenergicinterventions.J.Cardiovasc.Electrophysiol.3,2–16(1992).
8.Thomas,D.,Kiehn,J.,Katus,H.A.&Karle,C.A.Adrenergicregulationofthe
rapidcomponentofthecardiacdelayedrecti erpotassiumcurrent,I(Kr),andtheunderlyinghERGionchannel.BasicRes.Cardiol.99,279–287(2004).9.Cutler,M.J.,Jeyaraj,D.&Rosenbaum,D.S.Cardiacelectricalremodelingin
healthanddisease.TrendsPharmacol.Sci.32,174–180(2011).
10.Bers,D.M.Calciumcyclingandsignalingincardiacmyocytes.Annu.Rev.Physiol.70,23–49(2008).
11.Ieda,M.etal.Sema3amaintainsnormalheartrhythmthroughsympatheticinnervationpatterning.Nat.Med.13,604–612(2007).
12.Lorentz,C.U.etal.Heterogeneousventricularsympatheticinnervation,altered{beta}adrenergicreceptorexpression,andrhythminstabilityinmicelackingp75neurotrophinreceptor.Am.J.Physiol.HeartCirc.Physiol.298,H1652–H1660(2010).
13.Li,W.,Knowlton,D.,VanWinkle,D.M.&Habecker,B.A.Infarctionaltersboththedistributionandnoradrenergicpropertiesofcardiacsympatheticneurons.Am.J.Physiol.HeartCirc.Physiol.286,H2229–H2236(2004).
14.Dae,M.W.,O’Connell,J.W.,Botvinick,E.H.&Chin,M.C.Acuteandchroniceffectsoftransientmyocardialischemiaonsympatheticnerveactivity,density,andnorepinephrinecontent.Cardiovasc.Res.30,270–280(1995).
NATURECOMMUNICATIONS|6:6235|DOI:10.1038/ncomms7235|doc.guandang.net
(泛素激活酶) + ATP AMP + ppi O Ubi—C—S—E1 E2—SH(泛素结合酶) E1—SH O Ubi—C—S--E2 O Ubi—C—S--E2 targeting protein (E3(泛素...
profiling has been exploited to identify miRNA genes that may represent downstream targets of activated oncogenic pathways or that are targeting protein-...
7.细胞生物学蛋白分选 protein sorting_英语学习_外语学习_教育专区。Protein targeting or protein sorting Road map of protein sorting Golgi ? 1972年,C....
Protein design approaches for potential therapeutic applications targeting protein-protein interactions are Received: September 9, 2012; Revised: September 17, ...
4.2 蛋白质分拣的基本原理蛋白质分拣(protein targeting):蛋白质分类并 转运到正确的细胞内部位的过程 蛋白质的正确分拣的条件: ? 一是蛋白质中包含特殊的信号...
蛋白质的靶向输送(protein targeting) 蛋白质合成后需要经过复杂机制,定向输送到最终发挥生物功能的细胞靶部位, 这一过程称为蛋白质的靶向输送。目录 ? 信号序列(...
-MSH Endophin 三、高级结构的修饰(一)亚基聚合 (二)辅基连接(三)疏水脂链的共价连接 四、蛋白质合成后的靶向输送蛋白质的靶向输送(protein targeting) 蛋白...
(三)疏水脂链的共价连接 四、蛋白质合成后的靶向输送蛋白质的靶向输送(protein targeting) 蛋白质合成后需要经过复杂机制,定 向输送到最终发挥生物功能的细胞靶部...
Targeting protein (目标蛋白): amino acid sequence; molecular weight; theoretical extinction coefficient at 280 nm; isoelectric point (pI); Literature search ...
和蛋白质靶向运输(protein targeting)错误!未找到引用源。 错误 未找到引用源。 胞外的蛋白质经胞吞作用进入细胞内部, 也经历分选和靶向运输过程。 细胞中每一种...
热门文档